Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic

Abstract

IMPORTANCECancer treatment delay has been reported to variably impact cancer-specific survival and coronavirus disease 2019 (COVID-19)-specific mortality during the severe acute respiratory syndrome coronavirus 2 pandemic. During the pandemic, treatment delay is being recommended in a nonquantitative, nonobjective, and nonpersonalized manner, and this approach may be associated with suboptimal outcomes. Quantitative integration of cancer mortality estimates and data on the consequences of treatment delay is needed to aid treatment decisions and improve patient outcomes.OBJECTIVE To obtain quantitative integration of cancer-specific and COVID-19-specific mortality estimates that can be used to make optimal decisions for individual patients and optimize resource allocation. DESIGN, SETTING, AND PARTICIPANTSIn this decision analytical model, age-specific and stage-specific estimates of overall survival pre-COVID-19 were adjusted by the probability of COVID-19 (individualized by county, treatment-specific variables, hospital exposure frequency, and COVID-19 infectivity estimates), COVID-19 mortality (individualized by age-specific, comorbidity-specific, and treatment-specific variables), and delay of cancer treatment (impact and duration). These model estimates were integrated into a web application (OncCOVID) to calculate estimates of the cumulative overall survival and restricted mean survival time of patients who received immediate vs delayed cancer treatment. Using currently available information about COVID-19, a susceptible-infectedrecovered model that accounted for the increased risk among patients at health care treatment centers was developed. This model integrated the data on cancer mortality and the consequences of treatment delay to aid treatment decisions. Age-specific and cancer stage-specific estimates of overall survival pre-COVID-19 were extracted from the Surveillance, Epidemiology, and End Results database for 691 854 individuals with 25 cancer types who received cancer diagnoses in 2005 to 2006. Data from 5 436 896 individuals in the National Cancer Database were used to estimate the independent impact of treatment delay by cancer type and stage. In addition, data from 275 patients in a nested case-control study were used to estimate the COVID-19 mortality rate by age group and number of comorbidities. Data were analyzed from March 17 to May 21, 2020. EXPOSURES COVID-19 and cancer.MAIN OUTCOMES AND MEASURES Estimates of restricted mean survival time after the receipt of immediate vs delayed cancer treatment.

Severity of COVID-19 in patients with lung cancer: evidence and challenges

“… 66 As such, phase I trials have been disproportionately held. 65 Suspension of clinical activities has affected the ability to recruit patients, comply with protocol-mandated visits, and has affected the acquisition of laboratory and radiological data that are essential for both trial endpoints and correlative studies. 54 Many institutions have halted research-only blood draws and tissue collection and are only collecting samples that directly affect primary trial endpoints as long as patient safety is not compromised in doing so.…”

New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown

“…This would mean that patients with a new cancer are seen later, and can therefore potentially suffer from a delay in the start of their treatment. Therefore, it is important to assess the importance of such drop, as treatment delays can dramatically impact the prognosis of patients with cancer ( 7 ) ( 8 ).…”

Omission of adjuvant radiotherapy for older adults with early-stage breast cancer particularly in the COVID era: A literature review (on the behalf of Italian Association of Radiotherapy and Clinical Oncology)

“…Therefore, delay and/or reduction of the number of hospital and healthcare centers access is highly recommended, and it is a widely adopted strategy to reorganize therapeutic and outpatient activities of Radiation Oncology Departments during the crisis [ 70 ]. Since older adults are the population at higher mortality risk from COVID-19 and higher risk of severe consequences from COVID-19, they derive fewer benefits, in absolute terms, from postoperative RT [ 71 ].…”